Incyte Genomics and Lion Bioscience Collaborate to Provide Broader Access to Drug Target Information Strategic Collaboration To Make Industry-Leading LifeSeq® Database Available To Scientists Through Web-Based Integration Platform Palo Alto, CA, and Heidelberg, Germany/Cambridge, MA, April 2, 2002 – Incyte Genomics, Inc. (Nasdaq: INCY), the leading genomics information company, and LION bioscience, (Nasdaq: LEON, Neuer Markt: LIO, WKN 504 350), the leading provider of integrated information technology services for the life sciences, today announced an agreement to make Incyte's LifeSeq® Foundation information database available to life science researchers through the internet using LION's SRS integration platform. Financial terms were not disclosed. Incyte will license LION's SRS integration platform to provide LifeSeq® Foundation subscribers with a user-friendly web interface. Additionally, it will provide access to, and query functionality, across expanded information sources from the public domain that could enhance subscriber research efforts. A customized version of the LION integration platform will also serve as the interface for Incyte's LifeSeq Foundation on-line subscribers. LifeSeq® Foundation is the world's largest collection of pharmaceutically relevant full-length gene transcripts and contains the most comprehensive database of potential drug and therapeutic targets. Anchored to public genomic sequence data and annotated by Incyte's proprietary functional information and research tools, LifeSeq® Foundation is built on the strengths of LifeSeq Gold. It provides more than just sequence information - it delivers detailed information about gene function, enabling researchers to quickly begin validation experiments. In addition, LifeSeq® Foundation includes RNA expression data, genetic data in the form of single nucleotide polymorphisms (SNP) and comparative sequence information that provides homologues with rats and mice. Through LION's SRS platform, many scientists are already integrating their own data with data in the public domain. SRS enables its users to query diverse biological and scientific data through a single interface. Incyte and LION's collaboration to provide a user-friendly web interface, based on a customized version of SRS's integration technology, will allow LifeSeq® Foundation subscribers to retrieve and analyze Incyte's wealth of genomic and proteomic information together with publicly available data, eliminating the need for new hardware investment. In addition, LION customers can subscribe to and subsequently obtain information from LifeSeq® Foundation without having to shift from their current software platform with which they are familiar. "A strong information business is critical to our overall strategic plan," said Mike Lack, Chief Operating Officer at Incyte. "We are proud Incyte can now make the LifeSeq Foundation data more broadly accessible. The SRS software platform, already broadly used in the industry, allows for integration of public and proprietary information with only one interface that is scalable to fit their respective drug discovery efforts." "We are delighted to have the opportunity to provide the interface to the rich and comprehensive genomic, transcriptomic and proteomic information provided in the LifeSeq Foundation database," said Dr. Daniel Keesman, Executive Vice President Global Business of LION bioscience. "This partnership with Incyte underscores the position of LION's SRS technology as the industry standard for providing the most flexible, comprehensive and user-friendly integration solutions for content providers in the life sciences as well as in the pharmaceutical industry. LION's IT solutions allow companies to focus on their core competencies and capitalize on their IT investments by delivering content in the broadest and most efficient way and developing new products faster." The LION SRS platform with LifeSeq® Foundation is scheduled to be showcased at the Drug Discovery Conference in Boston in August 2002. About Incyte Genomics Incyte Genomics, Inc. has the largest commercial portfolio of issued United States patents covering human, full-length genes and the proteins they encode and is leveraging its leading intellectual property and genomic information position to be a leader in therapeutic small molecule, secreted protein and antibody discoveries. In addition, Incyte has also developed the leading integrated platform of genomic technologies designed to aid in the understanding of the molecular basis of disease. Incyte develops and markets genomic databases and licenses pharmaceutically relevant intellectual property. These offerings facilitate pharmaceutical and biotechnology researchers in their drug discovery and development; including gene discovery, understanding disease pathways, identifying new disease targets and the discovery and correlation of gene sequence variation to disease. For more information, visit Incyte's web site at www.incyte.com. LifeSeq® is a registered trademark of Incyte Genomics, Inc. in the United States and other countries. About LION bioscience AG LION bioscience (http://www.lionbioscience.com) provides proven information and knowledge management solutions to significantly improve life science R&D performance and productivity. These solutions integrate all R&D disciplines, spanning from genomics to early and late discovery through clinical trials. LION applies these solutions for its internal drug discovery program in the field of nuclear receptors with the goal to improve the overall productivity of the drug discovery process, outlicense validated target-lead combinations and partner with pharmaceutical companies on an IT-enhanced technology platform. Founded in 1997, LION has more than 500 employees, with headquarters in Heidelberg, Germany, and subsidiaries in Cambridge, UK, Cambridge, MA, Cleveland, OH, Columbus, OH, and San Diego, CA, USA. To date, LION has established partnerships with leading life science companies, including Aventis, Bayer, Boehringer Ingelheim, Celera, DuPont, GlaxoSmithKline, IBM, Janssen, Merck Inc., Nestle, Novartis, Paradigm Genetics, Pharmacia & Upjohn, Roche, Schering AG and Sumitomo Pharmaceuticals. Except for the historical information contained herein, the matters set forth in this press release, including without limitation statements as to the impact that the new Lion SRS software platform will have in accelerating the drug discovery and development efforts of pharmaceutical researchers and ultimately in bringing new medicines to market faster, at lower cost and with lower failure rates, the ability of Incyte's products and services to facilitate the research efforts of its customers, and Incyte's ability to leverage its intellectual property position to become a leader in therapeutic small molecule, secreted protein and antibody discoveries, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the ability of the parties to provide products and services that meet market needs and that beat other substantially similar products and services to market; the impact of competition and the ability of the parties to compete against competitors that may have greater financial and other resources; the availability of the financial resources necessary to fund the parties' business objectives; changes in technology; unanticipated delays or other issues that impact the effective marketing and sale of LifeSeq® Foundation; changes in the business plans of either party; Incyte's ability to obtain patent protection for its discoveries and to continue to be effective in expanding its patent coverage; and other risks detailed from time to time in Incyte's SEC reports, including its Annual Report on Form 10-K for the year ended December 31, 2001. Incyte disclaims any intent or obligation to update these forward-looking statements. All statements in this press release that are not historical are forward-looking statements within the meaning of the U.S. securities laws. Such statements are based on current expectations that are subject to risks and uncertainties. Actual results may vary materially from those projected because of factors such as uncertainties relating to technologies, product development, or manufacturing, market acceptance, cost or pricing of LION's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, or patent or copyright protection and litigation. These and other risk factors are discussed in LION's Annual Report on Form 20-F, dated October 16, 2001 as amended and filed with the Securities and Exchange Commission. LION expressly disclaims any obligation or undertaking to release publicly any updates, revisions or corrections to any forward-looking statements or historical information contained herein. LION bioscience®, i-biology®, bioSCOUT®, arraySCOUT™, arrayTAG™, arrayBASE™, genomeSCOUT™, pathSCOUT™, piSCOUT™, SRSeverEST™, iDEA™ and DiscoveryCenter™ are either registered trademarks of LION bioscience AG or its subsidiaries in the United States and/or other countries, or there are pending applications by LION bioscience AG or its subsidiaries for these trademarks in the United States and/or other countries. The names of actual companies and products mentioned herein may be the trademark of the respective owners.